PriceTargets.com logo

TransMedics Group - TMDX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $133.00
  • Forecasted Upside: -4.06%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$138.63 As of 12/4/2025 05:00 PM ET
▼ -1.47 (-1.05%)

This chart shows the closing price for TMDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TransMedics Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMDX

Analyst Price Target is $133.00
▼ -4.06% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $133.00, with a high forecast of $155.00 and a low forecast of $75.00. The average price target represents a -4.06% upside from the last price of $138.63.

This chart shows the closing price for TMDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in TransMedics Group. This rating has held steady since November 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$123.00 ➝ $135.00
10/30/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$142.00 ➝ $147.00
10/30/2025Needham & Company LLCReiterated RatingBuy ➝ Buy
10/30/2025Piper SandlerLower TargetOverweight ➝ Overweight$145.00 ➝ $140.00
10/23/2025Needham & Company LLCUpgradeHold ➝ Buy$148.00
10/14/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$142.00
10/13/2025Jefferies Financial GroupInitiated CoverageBuy$145.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/6/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
9/29/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/16/2025Evercore ISIInitiated CoverageOutperform$155.00
9/4/2025Stifel NicolausInitiated CoverageHold$115.00
8/25/2025Needham & Company LLCReiterated RatingHold ➝ Hold
8/1/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$115.00 ➝ $123.00
7/15/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$129.00 ➝ $142.00
6/17/2025OppenheimerBoost TargetOutperform ➝ Outperform$130.00 ➝ $150.00
6/17/2025Needham & Company LLCReiterated RatingHold ➝ Hold
6/4/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.00
6/3/2025Needham & Company LLCReiterated RatingHold ➝ Hold
5/9/2025OppenheimerBoost TargetOutperform ➝ Outperform$125.00 ➝ $130.00
5/9/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00
4/29/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$90.00 ➝ $105.00
4/23/2025Needham & Company LLCReiterated RatingHold ➝ Hold
3/26/2025Needham & Company LLCReiterated RatingHold ➝ Hold
3/11/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
2/5/2025Needham & Company LLCReiterated RatingHold ➝ Hold
12/17/2024JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$116.00 ➝ $75.00
12/11/2024Needham & Company LLCReiterated RatingHold ➝ Hold
12/11/2024Robert W. BairdLower TargetOutperform ➝ Outperform$150.00 ➝ $120.00
12/11/2024Piper SandlerLower TargetOverweight ➝ Overweight$110.00 ➝ $90.00
12/3/2024OppenheimerReiterated RatingOutperform ➝ Outperform$125.00 ➝ $125.00
12/3/2024Needham & Company LLCReiterated RatingHold ➝ Hold
11/22/2024Needham & Company LLCReiterated RatingBuy ➝ Hold$109.00 ➝ $109.00
11/20/2024Piper SandlerLower TargetOverweight ➝ Overweight$180.00 ➝ $110.00
11/20/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$109.00 ➝ $104.00
11/18/2024TD CowenLower TargetBuy ➝ Buy$175.00 ➝ $120.00
10/29/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$180.00 ➝ $180.00
10/29/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$173.00 ➝ $116.00
10/29/2024Robert W. BairdLower TargetOutperform ➝ Outperform$200.00 ➝ $150.00
10/29/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$169.00 ➝ $109.00
10/29/2024OppenheimerLower TargetOutperform ➝ Outperform$200.00 ➝ $125.00
10/29/2024Needham & Company LLCLower TargetBuy ➝ Buy$208.00 ➝ $109.00
10/7/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$180.00 ➝ $180.00
9/24/2024Baird R WUpgradeStrong-Buy
9/24/2024Robert W. BairdInitiated CoverageOutperform$200.00
8/21/2024Needham & Company LLCInitiated CoverageBuy ➝ Buy$208.00 ➝ $208.00
8/2/2024StephensBoost TargetOverweight ➝ Overweight$151.00 ➝ $178.00
8/1/2024Piper SandlerBoost TargetOverweight ➝ Overweight$170.00 ➝ $180.00
8/1/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$117.00 ➝ $169.00
8/1/2024OppenheimerBoost TargetOutperform ➝ Outperform$125.00 ➝ $200.00
7/15/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$104.00 ➝ $145.00
7/15/2024Piper SandlerBoost TargetOverweight ➝ Overweight$120.00 ➝ $170.00
6/21/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$120.00 ➝ $120.00
6/7/2024TD CowenBoost TargetBuy ➝ Buy$130.00 ➝ $175.00
6/6/2024Cantor FitzgeraldInitiated CoverageOverweight$161.00
6/4/2024StephensInitiated CoverageOverweight$151.00
5/1/2024TD CowenBoost TargetBuy ➝ Buy$100.00 ➝ $130.00
5/1/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$102.00 ➝ $117.00
5/1/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$105.00 ➝ $127.00
5/1/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$95.00 ➝ $120.00
5/1/2024OppenheimerBoost TargetOutperform ➝ Outperform$105.00 ➝ $125.00
3/28/2024Piper SandlerInitiated CoverageOverweight$95.00
2/28/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$75.00 ➝ $95.00
2/27/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$87.00 ➝ $105.00
2/27/2024OppenheimerBoost TargetOutperform ➝ Outperform$92.00 ➝ $105.00
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$54.00 ➝ $75.00
11/7/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$67.00 ➝ $70.00
11/7/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$50.00 ➝ $54.00
10/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$81.00 ➝ $50.00
8/4/2023TD CowenBoost TargetOutperform ➝ Outperform$95.00 ➝ $110.00
8/4/2023OppenheimerBoost Target$90.00 ➝ $92.00
7/19/2023Robert W. BairdInitiated CoverageOutperform
7/19/2023William BlairReiterated RatingOutperform
5/2/2023OppenheimerBoost Target$85.00 ➝ $90.00
2/23/2023JPMorgan Chase & Co.Boost TargetOverweight$67.00 ➝ $81.00
2/23/2023Canaccord Genuity GroupBoost TargetBuy$68.00 ➝ $78.00
2/23/2023Morgan StanleyBoost TargetEqual Weight$63.00 ➝ $74.00
2/23/2023CowenBoost TargetOutperform$70.00 ➝ $75.00
2/23/2023OppenheimerBoost TargetOutperform$55.00 ➝ $85.00
1/6/2023Morgan StanleyBoost TargetEqual Weight$54.00 ➝ $63.00
12/16/2022CowenBoost Target$60.00 ➝ $70.00
11/4/2022Morgan StanleyBoost TargetEqual Weight$45.00 ➝ $54.00
11/4/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$58.00 ➝ $63.00
10/11/2022Morgan StanleyBoost TargetEqual Weight$37.00 ➝ $45.00
8/4/2022Canaccord Genuity GroupBoost Target$46.00 ➝ $58.00
8/3/2022Morgan StanleyBoost TargetEqual Weight$34.00 ➝ $37.00
8/2/2022OppenheimerBoost TargetOutperform$40.00 ➝ $45.00
8/2/2022CowenBoost Target$45.00 ➝ $50.00
8/2/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$26.00 ➝ $48.00
7/26/2022CowenBoost TargetOutperform$39.00 ➝ $45.00
6/29/2022Morgan StanleyBoost TargetEqual Weight$25.00 ➝ $34.00
6/28/2022CowenBoost TargetOutperform$35.00 ➝ $39.00
5/4/2022Canaccord Genuity GroupBoost Target$39.00 ➝ $46.00
5/4/2022CowenBoost Target$28.00 ➝ $35.00
3/17/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$38.00 ➝ $39.00
2/25/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $15.00
2/25/2022Canaccord Genuity GroupLower Target$79.00 ➝ $38.00
2/24/2022JPMorgan Chase & Co.Lower Target$20.00 ➝ $12.00
1/7/2022Morgan StanleyLower TargetEqual Weight$33.00 ➝ $22.00
10/14/2021JPMorgan Chase & Co.Boost TargetNeutral$29.00 ➝ $30.00
10/8/2021CowenLower TargetOutperform$49.00 ➝ $39.00
7/8/2021OppenheimerInitiated CoverageBuy$49.00
6/18/2021CowenReiterated RatingBuy$49.00
5/5/2021Morgan StanleyLower TargetEqual Weight$38.00 ➝ $35.00
3/29/2021CowenBoost TargetPositive ➝ Outperform$44.00 ➝ $49.00
3/3/2021Morgan StanleyBoost TargetEqual Weight$16.00 ➝ $38.00
3/2/2021OppenheimerBoost TargetHold ➝ Outperform$25.00 ➝ $40.00
2/24/2021CowenBoost TargetOutperform$20.00 ➝ $44.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.39 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 27 very positive mentions
  • 38 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
5/8/2025
  • 41 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 17 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 23 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 28 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 14 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 27 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 35 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 35 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $138.63
Low: $133.50
High: $139.75

50 Day Range

MA: $124.55
Low: $107.29
High: $150.42

52 Week Range

Now: $138.63
Low: $55.00
High: $156.00

Volume

644,815 shs

Average Volume

813,568 shs

Market Capitalization

$4.74 billion

P/E Ratio

56.13

Dividend Yield

N/A

Beta

2.06

Frequently Asked Questions

What sell-side analysts currently cover shares of TransMedics Group?

The following Wall Street research analysts have issued stock ratings on TransMedics Group in the last year: Canaccord Genuity Group Inc., Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings, Inc., Piper Sandler, Robert W. Baird, Stifel Nicolaus, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for TMDX.

What is the current price target for TransMedics Group?

0 Wall Street analysts have set twelve-month price targets for TransMedics Group in the last year. Their average twelve-month price target is $133.00, suggesting a possible downside of 4.1%. Evercore ISI has the highest price target set, predicting TMDX will reach $155.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $75.00 for TransMedics Group in the next year.
View the latest price targets for TMDX.

What is the current consensus analyst rating for TransMedics Group?

TransMedics Group currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TMDX.

What other companies compete with TransMedics Group?

Other companies that are similar to TransMedics Group include Zimmer Biomet, Solventum, Smith & Nephew SNATS, Penumbra and Stevanato Group. Learn More about companies similar to TransMedics Group.

How do I contact TransMedics Group's investor relations team?

TransMedics Group's physical mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company's listed phone number is (978) 552-0900 and its investor relations email address is [email protected]. The official website for TransMedics Group is www.transmedics.com. Learn More about contacing TransMedics Group investor relations.